Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2
{{output}}
Background: Chronic spontaneous urticaria (CSU) substantially reduces patient quality of life (QoL); therefore, it is crucial to include QoL-related patient-reported outcome measures (PROMs) when assessing treatment efficacy. ... ...
